Can You Take Simvastatin and Itraconazole Together?

No. According to the FDA drug label for simvastatin, itraconazole is contraindicated—meaning the drugs should not be used together. The official prescribing guidance states that if treatment with itraconazole is unavoidable, simvastatin therapy must be suspended during the course of itraconazole treatment. This is the most restrictive classification for a drug interaction, and it reflects a serious safety concern.

What the Source Says

The source for this information is the FDA drug label for simvastatin, which lists itraconazole among a category of strong CYP3A4 inhibitors that carry an elevated risk of myopathy and rhabdomyolysis when combined with simvastatin. The prescribing recommendation is unambiguous: the combination is contraindicated.

The exact language from the label reads: "If treatment with itraconazole, ketoconazole, posaconazole, voriconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin must be suspended during the course of treatment."

This guidance appears in multiple sections of the label that address drug interactions and the risk of muscle-related adverse effects. The label does not provide a specific incidence rate or describe mechanism details in the supplied source record, but the classification as contraindicated places this interaction in the highest-severity category.

How to Understand This

To understand why this interaction is so serious, it helps to know a bit about how both drugs work in your body.

Simvastatin and cholesterol metabolism: Simvastatin is a statin—a class of medications used to lower cholesterol and reduce the risk of heart disease. Simvastatin is broken down (metabolized) in your body by an enzyme system called the cytochrome P450 system, specifically an enzyme called CYP3A4. This enzyme lives in your liver and intestines and is responsible for processing many medications.

Itraconazole and enzyme inhibition: Itraconazole is an antifungal medication used to treat fungal infections. It is a strong CYP3A4 inhibitor, meaning it powerfully blocks or slows the CYP3A4 enzyme. When CYP3A4 is inhibited, it cannot break down simvastatin at its normal rate. This causes simvastatin to accumulate in your bloodstream to much higher levels than they would be if you were taking simvastatin alone.

The muscle toxicity risk: Statins carry an inherent risk of muscle problems, ranging from muscle pain and weakness (myopathy) to a severe, potentially life-threatening condition called rhabdomyolysis, in which muscle tissue breaks down rapidly and releases its contents into the bloodstream. This breakdown can cause acute kidney injury and other serious complications. Higher blood levels of simvastatin increase this risk significantly. When itraconazole prevents normal simvastatin clearance, the drug stays in your system longer and at higher concentrations, amplifying the myopathy and rhabdomyolysis risk.

What the source does and does not tell us: The FDA label identifies itraconazole as a contraindicated agent based on this documented risk, but the supplied source record does not specify the exact mechanism of how simvastatin buildup leads to muscle injury at the cellular level. What we know is that the risk is real and well-recognized enough to warrant the most restrictive recommendation: do not combine these drugs, and if itraconazole treatment is necessary, stop simvastatin while taking it.

Who Should Pay Particular Attention

Anyone prescribed or considering both simvastatin and itraconazole should inform their pharmacist or physician immediately. This applies whether you are starting one drug while already taking the other, or if both are being considered as new prescriptions.

Patients with a personal history of statin-related muscle problems, or those taking multiple medications that interact with CYP3A4, should be especially vigilant. However, the contraindication applies to all patients—it is not limited to specific age groups, kidney function levels, or liver conditions, though a pharmacist or physician may consider those factors when deciding on an alternative treatment.

Hypothetical Examples

Scenario 1: You are taking simvastatin 20 mg daily for high cholesterol. Your doctor diagnoses a fungal nail infection and prescribes itraconazole. Before you fill the itraconazole prescription or take your next simvastatin dose, you check your medications with your pharmacist. Your pharmacist alerts you to the contraindication and contacts your doctor. Your doctor either chooses a different antifungal medication (one that does not inhibit CYP3A4) or temporarily stops your simvastatin for the duration of itraconazole treatment, with a plan to restart simvastatin after itraconazole is finished. This coordination prevents simvastatin buildup and the associated muscle toxicity risk.

Scenario 2: You are admitted to the hospital with a serious systemic fungal infection and your doctor determines that itraconazole is the necessary treatment. Your admission notes list simvastatin as a home medication. A physician or clinical pharmacist reviews your drug list, identifies the contraindication, and makes a deliberate decision to suspend simvastatin during your itraconazole course. Your team monitors you for muscle symptoms and plans simvastatin reinitiation once itraconazole is complete. This deliberate suspension follows the FDA label guidance for situations where itraconazole treatment is unavoidable.

What to Discuss With a Pharmacist or Physician

If you are taking simvastatin and your doctor prescribes or suggests itraconazole (or vice versa), ask the following:

• Is there an alternative antifungal medication? Itraconazole is not the only antifungal option. Your doctor or pharmacist may be able to recommend a different agent that does not inhibit CYP3A4 or that carries a lower interaction risk. Common alternatives include terbinafine (oral), fluconazole, or others, depending on the type and severity of your fungal infection.
• If itraconazole is necessary, what is the plan for simvastatin? According to the FDA label, simvastatin should be suspended during itraconazole treatment. Ask your doctor for specific instructions: when to stop simvastatin, when to restart it (usually after itraconazole is finished), and whether any monitoring or follow-up lab work is needed.
• How long will itraconazole treatment last? Knowing the duration helps your pharmacist or physician plan when simvastatin can safely resume.
• Are there any symptoms I should watch for? Although you will not be taking simvastatin during itraconazole, your pharmacist or physician can explain muscle pain, weakness, or dark urine—signs that would warrant immediate medical attention if they occurred during or shortly after treatment.
• Do I need any lab work? Some patients benefit from baseline or follow-up liver and muscle enzyme tests (such as creatine kinase) before and after itraconazole, especially if other risk factors are present. Your provider will advise based on your individual situation.

Do not stop, start, skip, or change the dose of either medication on your own. These decisions require coordination between your doctor and pharmacist to ensure your fungal infection is treated effectively and your cholesterol management continues safely.

Key Takeaways

• Contraindicated combination: The FDA drug label for simvastatin lists itraconazole as contraindicated, the most restrictive interaction classification.
• Mechanism: Itraconazole is a strong inhibitor of the CYP3A4 enzyme, which normally breaks down simvastatin. When CYP3A4 is blocked, simvastatin accumulates to dangerously high levels in the bloodstream.
• Primary risk: High simvastatin levels increase the risk of myopathy (muscle damage) and rhabdomyolysis (severe muscle breakdown), both of which can be serious or life-threatening.
• FDA guidance: If itraconazole treatment is unavoidable, simvastatin must be suspended during the course of antifungal therapy.
• Action step: Always alert your pharmacist and physician if you are taking or considering both drugs, and ask about alternative antifungal options or a plan to temporarily stop simvastatin.

Sources

• DailyMed – FDA Drug Labels (Simvastatin prescribing information)
• Open FDA – Drug Information Search
• RxNorm – Drug Name and Classification Search
• PubMed – Literature on CYP3A4 interactions and statin safety

This article explains what the FDA drug label says about the interaction between simvastatin and itraconazole, but it is not a substitute for professional medical advice. Your specific medical history, other medications, and individual risk factors all matter. If you are taking simvastatin or have been prescribed itraconazole, check your full medication list at checkdruginteractions.com to identify other possible interactions, and confirm any changes to your medications with your pharmacist or physician before taking action. They can review your complete health picture and help you make the safest choice.